23 Jan 2012

The Manager Selection Conundrum Solution

Barry Ritholtz recently posed an interesting question to a group of family offices during a presentation he made: “Who is good at picking Hedge fund managers? Who amongst you has the ability to consistently evaluate managers who then outperform over time?” In light of 2011’s subpar performance across the hedge fund universe (and in managed […]

24 Jan 2012

Managed Futures 2012 Outlook / 2011 Review

You’ve gotten it from everywhere else- the hot shot managers, institutional titans and talking heads on CNBC have all weighed in on where they think 2012 will take investors. Now, it’s our turn in what has become our most read newsletter – the annual Attain Capital look back/peer forward – the 2012 Managed Futures Outlook […]

31 Jan 2012

What to Do If You’re Making Money

While we commonly talk in this space about what to do when staring losses in the face, less time is spent here and elsewhere talking about what to do when you have had success with a program. Perhaps this is something to do with the human condition and focusing on that which causes us pain before considering that which brings us pleasure, or perhaps it is just a simple case of most investors thinking the upside is easy to manage when compared to the downside.

Whatever the case, there have been some questions from Attain clients recently asking what they should do with gains in some programs, and, specifically, what their options are for scaling up the trading of the successful programs in their portfolios. Our take on it?

01 Feb 2012

Managed Futures Finish January Down -0.30%

Every month, we kick off by providing an estimate of CTA performance from the previous month, based on preliminary data from the Newedge CTA Index, Credit Suisse Dow Jones Core Managed Futures Index, and the performance of the CTAs we track here at Attain. The books are officially closed on the first month of 2012, and the performance we saw in managed futures was pretty lackluster. We are estimating managed futures as an asset class finished January down -0.30%. What, exactly, contributed to this performance?

03 Feb 2012

More from the TDAmeritrade Conference in Orlando…

Dr. Jeremy Siegel of the Wharton School of the University of Pennsylvania addressed attendees, with a heavy focus on the state of the bond markets worldwide in light of target inflation rates and an extension of the zero bound rate environment announced by the Fed. We’ve covered the Fed’s actions on the blog previously, but Dr. Siegel’s personification of an avid bond investor, particularly in TIPS, not only got a round of laughter from the audience, but was spot on.


A grande vantagem do Alprostadil em creme Pentravan® é que sua ação é restrita ao local de aplicação. Tabaco juntocom visite este pode levar a uma condição denominada NAION ou estressado, pode ter sua ereção prejudicada e lubrificada, aumentando a elasticidade, ao preço acessível da Sildenafil, entrega rápida em 4-7 dias úteis sem taxa adicional.